Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Circulating immune complexes (CICs) are implicated in various diseases.
• Polymorphic epithelial mucin (PEM/MUC-1) is a tumor-associated antigen relevant in breast and ovarian cancers.
• Commercial immunoassays like CA 15-3 are used for cancer monitoring.

Purpose of the Study:

• To investigate the presence of CICs containing PEM/MUC-1 in cancer patients.
• To determine the impact of these CICs on the detection of circulating PEM/MUC-1 by the CA 15-3 assay.

Main Methods:

• Sera from breast carcinoma, ovarian carcinoma, benign breast tumor patients, and healthy individuals were analyzed.
• Detection of CICs containing PEM/MUC-1.
• Correlation analysis between PEM-containing immune complexes (PEM-CICs) and CA 15-3 levels.
• Isolation of PEM from sera.

Main Results:

• CICs containing PEM/MUC-1 were found in 24.5% of primary breast carcinoma patients and 18-21.4% of advanced ovarian and breast carcinoma patients.
• A significant percentage (37%) of benign breast tumor patients also showed PEM-CICs.
• A negative correlation was observed between PEM-CICs and CA 15-3 values, indicating that PEM can be masked within CICs.
• PEM was successfully isolated from CA 15-3-negative sera containing high levels of PEM-CICs.
• Predominantly IgG antibodies were found in PEM-CICs, suggesting specific immune responses.

Conclusions:

• The presence of PEM-containing CICs is a significant finding in cancer patients, including those with benign tumors.
• PEM-CICs can interfere with the accuracy of circulating tumor marker detection assays like CA 15-3.
• This interference may affect the clinical utility of CA 15-3 for monitoring cancer patients.
• Further research is needed to understand the clinical implications of PEM-CICs in cancer diagnosis and management.